TY - JOUR AU - Menon, M. P. AU - Pittaluga, S. AU - Jaffe, E. S. PY - 2012 DA - 2012// TI - The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification JO - Cancer J VL - 18 UR - https://doi.org/10.1097/PPO.0b013e31826aee97 DO - 10.1097/PPO.0b013e31826aee97 ID - Menon2012 ER - TY - JOUR AU - Juarez-Salcedo, L. M. AU - Sandoval-Sus, J. AU - Sokol, L. AU - Chavez, J. C. AU - Dalia, S. PY - 2017 DA - 2017// TI - The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: the future is now JO - Crit Rev Oncol Hematol VL - 113 UR - https://doi.org/10.1016/j.critrevonc.2017.02.027 DO - 10.1016/j.critrevonc.2017.02.027 ID - Juarez-Salcedo2017 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Kataoka, K. AU - Shiraishi, Y. AU - Takeda, Y. AU - Sakata, S. AU - Matsumoto, M. AU - Nagano, S. PY - 2016 DA - 2016// TI - Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers JO - Nature. VL - 534 UR - https://doi.org/10.1038/nature18294 DO - 10.1038/nature18294 ID - Kataoka2016 ER - TY - STD TI - Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of Atezolizumab in PD-L1-selected patients with non-small-cell lung Cancer. J Thorac Oncol. 2018. https://doi.org/10.1016/j.jtho.2018.05.004. ID - ref5 ER - TY - JOUR AU - Ma, G. AU - Deng, Y. AU - Jiang, H. AU - Li, W. AU - Wu, Q. AU - Zhou, Q. PY - 2018 DA - 2018// TI - The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: an updated meta-analysis JO - Clin Chim Acta VL - 482 UR - https://doi.org/10.1016/j.cca.2018.03.038 DO - 10.1016/j.cca.2018.03.038 ID - Ma2018 ER - TY - JOUR AU - Abdel-Rahman, O. PY - 2016 DA - 2016// TI - PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis JO - Immunotherapy. VL - 8 UR - https://doi.org/10.2217/imt-2016-0025 DO - 10.2217/imt-2016-0025 ID - Abdel-Rahman2016 ER - TY - JOUR AU - Wang, Z. AU - Peng, S. AU - Xie, H. AU - Guo, L. AU - Cai, Q. AU - Shang, Z. PY - 2018 DA - 2018// TI - Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals JO - Clin Exp Med VL - 18 UR - https://doi.org/10.1007/s10238-018-0488-3 DO - 10.1007/s10238-018-0488-3 ID - Wang2018 ER - TY - JOUR AU - McKay, R. R. AU - Bosse, D. AU - Xie, W. AU - Wankowicz, S. A. M. AU - Flaifel, A. AU - Brandao, R. PY - 2018 DA - 2018// TI - The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma JO - Cancer Immunol Res VL - 6 UR - https://doi.org/10.1158/2326-6066.CIR-17-0475 DO - 10.1158/2326-6066.CIR-17-0475 ID - McKay2018 ER - TY - JOUR AU - Younes, A. AU - Santoro, A. AU - Shipp, M. AU - Zinzani, P. L. AU - Timmerman, J. M. AU - Ansell, S. PY - 2016 DA - 2016// TI - Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30167-X DO - 10.1016/S1470-2045(16)30167-X ID - Younes2016 ER - TY - JOUR AU - Kiyasu, J. AU - Miyoshi, H. AU - Hirata, A. AU - Arakawa, F. AU - Ichikawa, A. AU - Niino, D. PY - 2015 DA - 2015// TI - Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma JO - Blood. VL - 126 UR - https://doi.org/10.1182/blood-2015-02-629600 DO - 10.1182/blood-2015-02-629600 ID - Kiyasu2015 ER - TY - JOUR AU - Rossille, D. AU - Gressier, M. AU - Damotte, D. AU - Maucort-Boulch, D. AU - Pangault, C. AU - Semana, G. PY - 2014 DA - 2014// TI - High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial JO - Leukemia. VL - 28 UR - https://doi.org/10.1038/leu.2014.137 DO - 10.1038/leu.2014.137 ID - Rossille2014 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - PLoS Med VL - 6 UR - https://doi.org/10.1371/journal.pmed.1000097 DO - 10.1371/journal.pmed.1000097 ID - Moher2009 ER - TY - JOUR AU - Parmar, M. K. AU - Torri, V. AU - Stewart, L. PY - 1998 DA - 1998// TI - Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints JO - Stat Med VL - 17 UR - https://doi.org/3.0.CO;2-8 DO - 3.0.CO;2-8 ID - Parmar1998 ER - TY - JOUR AU - Stang, A. PY - 2010 DA - 2010// TI - Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses JO - Eur J Epidemiol VL - 25 UR - https://doi.org/10.1007/s10654-010-9491-z DO - 10.1007/s10654-010-9491-z ID - Stang2010 ER - TY - JOUR AU - Xing, W. AU - Dresser, K. AU - Zhang, R. AU - Evens, A. M. AU - Yu, H. AU - Woda, B. A. PY - 2016 DA - 2016// TI - PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: Clinicopathologic features and prognostic implications JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.11045 DO - 10.18632/oncotarget.11045 ID - Xing2016 ER - TY - JOUR AU - Kwon, D. AU - Kim, S. AU - Kim, P. J. AU - Go, H. AU - Nam, S. J. AU - Paik, J. H. PY - 2016 DA - 2016// TI - Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas JO - Histopathology. VL - 68 UR - https://doi.org/10.1111/his.12882 DO - 10.1111/his.12882 ID - Kwon2016 ER - TY - JOUR AU - Dong, L. AU - Lv, H. AU - Li, W. AU - Song, Z. AU - Li, L. AU - Zhou, S. PY - 2016 DA - 2016// TI - Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.9061 DO - 10.18632/oncotarget.9061 ID - Dong2016 ER - TY - JOUR AU - Four, M. AU - Cacheux, V. AU - Tempier, A. AU - Platero, D. AU - Fabbro, M. AU - Marin, G. PY - 2017 DA - 2017// TI - PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival JO - Hematol Oncol VL - 35 UR - https://doi.org/10.1002/hon.2375 DO - 10.1002/hon.2375 ID - Four2017 ER - TY - JOUR AU - Bledsoe, J. R. AU - Redd, R. A. AU - Hasserjian, R. P. AU - Soumerai, J. D. AU - Nishino, H. T. AU - Boyer, D. F. PY - 2016 DA - 2016// TI - The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome JO - Am J Hematol VL - 91 UR - https://doi.org/10.1002/ajh.24485 DO - 10.1002/ajh.24485 ID - Bledsoe2016 ER - TY - JOUR AU - Hu, L. Y. AU - Xu, X. L. AU - Rao, H. L. AU - Chen, J. AU - Lai, R. C. AU - Huang, H. Q. PY - 2017 DA - 2017// TI - Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study JO - Chin J Cancer VL - 36 UR - https://doi.org/10.1186/s40880-017-0262-z DO - 10.1186/s40880-017-0262-z ID - Hu2017 ER - TY - JOUR AU - Fang, X. AU - Xiu, B. AU - Yang, Z. AU - Qiu, W. AU - Zhang, L. AU - Zhang, S. PY - 2017 DA - 2017// TI - The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma JO - Medicine (Baltimore) VL - 96 UR - https://doi.org/10.1097/MD.0000000000006398 DO - 10.1097/MD.0000000000006398 ID - Fang2017 ER - TY - JOUR AU - Liu, Y. AU - Ma, J. AU - Yu, K. AU - Li, M. AU - Liu, F. AU - Yan, Q. PY - 2018 DA - 2018// TI - Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas JO - Pathol Res Pract VL - 214 UR - https://doi.org/10.1016/j.prp.2018.03.001 DO - 10.1016/j.prp.2018.03.001 ID - Liu2018 ER - TY - JOUR AU - Ishikawa, E. AU - Kato, S. AU - Shimada, K. AU - Tanaka, T. AU - Suzuki, Y. AU - Satou, A. PY - 2018 DA - 2018// TI - Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells JO - Cancer Med VL - 7 UR - https://doi.org/10.1002/cam4.1875 DO - 10.1002/cam4.1875 ID - Ishikawa2018 ER - TY - STD TI - Sun C, Jia Y, Wang W, Bi R, Wu L, Bai Q, et al. Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma. Histopathology. 2018. https://doi.org/10.1111/his.13765. ID - ref25 ER - TY - JOUR AU - Kwon, H. J. AU - Yang, J. M. AU - Lee, J. O. AU - Lee, J. S. AU - Paik, J. H. PY - 2018 DA - 2018// TI - Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma JO - J Transl Med VL - 16 UR - https://doi.org/10.1186/s12967-018-1689-y DO - 10.1186/s12967-018-1689-y ID - Kwon2018 ER - TY - JOUR AU - Shi, Y. AU - Deng, L. AU - Song, Y. AU - Lin, D. AU - Lai, Y. AU - Zhou, L. PY - 2018 DA - 2018// TI - CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients JO - Int J Hematol VL - 108 UR - https://doi.org/10.1007/s12185-018-2466-7 DO - 10.1007/s12185-018-2466-7 ID - Shi2018 ER - TY - JOUR AU - Hans, C. P. AU - Weisenburger, D. D. AU - Greiner, T. C. AU - Gascoyne, R. D. AU - Delabie, J. AU - Ott, G. PY - 2004 DA - 2004// TI - Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray JO - Blood. VL - 103 UR - https://doi.org/10.1182/blood-2003-05-1545 DO - 10.1182/blood-2003-05-1545 ID - Hans2004 ER - TY - JOUR AU - Liu, J. AU - Quan, L. AU - Zhang, C. AU - Liu, A. AU - Tong, D. AU - Wang, J. PY - 2018 DA - 2018// TI - Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen JO - Oncol Lett VL - 15 ID - Liu2018 ER - TY - JOUR AU - Lesokhin, A. M. AU - Ansell, S. M. AU - Armand, P. AU - Scott, E. C. AU - Halwani, A. AU - Gutierrez, M. PY - 2016 DA - 2016// TI - Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.9789 DO - 10.1200/JCO.2015.65.9789 ID - Lesokhin2016 ER - TY - JOUR AU - Armand, P. AU - Nagler, A. AU - Weller, E. A. AU - Devine, S. M. AU - Avigan, D. E. AU - Chen, Y. B. PY - 2013 DA - 2013// TI - Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large b-cell lymphoma: results of an international phase II trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.3685 DO - 10.1200/JCO.2012.48.3685 ID - Armand2013 ER - TY - JOUR AU - Chen, B. J. AU - Chapuy, B. AU - Ouyang, J. AU - Sun, H. H. AU - Roemer, M. G. M. AU - Xu, M. L. PY - 2013 DA - 2013// TI - PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0855 DO - 10.1158/1078-0432.CCR-13-0855 ID - Chen2013 ER - TY - JOUR AU - Georgiou, K. AU - Chen, L. AU - Berglund, M. AU - Ren, W. AU - Miranda, N. F. C. C. AU - Lisboa, S. PY - 2016 DA - 2016// TI - Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-12-686550 DO - 10.1182/blood-2015-12-686550 ID - Georgiou2016 ER - TY - JOUR AU - Green, M. R. AU - Monti, S. AU - Rodig, S. J. AU - Juszczynski, P. AU - Currie, T. AU - O'Donnell, E. PY - 2010 DA - 2010// TI - Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma JO - Blood. VL - 116 UR - https://doi.org/10.1182/blood-2010-05-282780 DO - 10.1182/blood-2010-05-282780 ID - Green2010 ER - TY - JOUR AU - Ma, J. AU - Xing, W. AU - Coffey, G. AU - Dresser, K. AU - Lu, K. AU - Guo, A. PY - 2015 DA - 2015// TI - Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.6316 DO - 10.18632/oncotarget.6316 ID - Ma2015 ER - TY - JOUR AU - Jagannathan, G. AU - Gong, J. AU - Uppal, G. PY - 2018 DA - 2018// TI - EBV+ diffuse large b-cell lymphoma, nos shows over-expression of PD-L1/PD-1 JO - Lab Investig VL - 98 UR - https://doi.org/10.1038/s41374-017-0010-7 DO - 10.1038/s41374-017-0010-7 ID - Jagannathan2018 ER - TY - JOUR AU - Boyer, D. F. AU - McKelvie, P. A. AU - Leval, L. AU - Edlefsen, K. L. AU - Ko, Y. H. AU - Aberman, Z. A. PY - 2017 DA - 2017// TI - Fibrin-associated EBV-positive large B-cell lymphoma: an indolent neoplasm with features distinct from diffuse large B-cell lymphoma associated with chronic inflammation JO - Am J Surg Pathol VL - 41 UR - https://doi.org/10.1097/PAS.0000000000000775 DO - 10.1097/PAS.0000000000000775 ID - Boyer2017 ER - TY - JOUR AU - Green, M. R. AU - Rodig, S. AU - Juszczynski, P. AU - Ouyang, J. AU - Sinha, P. AU - O'Donnell, E. PY - 2012 DA - 2012// TI - Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1942 DO - 10.1158/1078-0432.CCR-11-1942 ID - Green2012 ER - TY - JOUR AU - He, X. AU - Chen, Z. AU - Fu, T. AU - Jin, X. AU - Yu, T. AU - Liang, Y. PY - 2014 DA - 2014// TI - Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-153 DO - 10.1186/1471-2407-14-153 ID - He2014 ER - TY - JOUR AU - Hu, S. AU - Xu-Monette, Z. Y. AU - Tzankov, A. AU - Green, T. AU - Wu, L. AU - Balasubramanyam, A. PY - 2013 DA - 2013// TI - MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2012-10-460063 DO - 10.1182/blood-2012-10-460063 ID - Hu2013 ER -